Anteris Technologies Global Corp.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Anteris Technologies Global Corp. operates as a structural heart company, dedicating its efforts to the discovery, advancement, and commercialization of innovative medical devices aimed at enhancing patient well-being, particularly for those with aortic stenosis. The company's primary innovation is the DurAVR transcatheter heart valve system, a pioneering single-piece, biomimetic transcatheter aortic valve. This valve is specifically engineered to replicate the form and function of a healthy native aortic valve, promoting natural, laminar blood flow. Complementing its flagship valve, the firm develops ADAPT anti-calcification tissue, a proprietary bovine pericardial tissue engineering process. This advanced preparation transforms xenograft tissue into robust bioscaffolds that exhibit long-term durability and have been clinically demonstrated to remain free of calcification for up to a decade, finding widespread use in various surgical repair applications, including cardiac and vascular patches. Furthermore, Anteris provides the ComASUR delivery system, a specialized balloon-expandable platform co-developed with physicians. This system incorporates a reinforced, steerable catheter, enabling highly precise and controlled delivery of the DurAVR valve within the intricate heart anatomy, minimizing potential damage. Anteris Technologies Global Corp. was founded in 1999 and is headquartered in Toowong, Australia, with a significant operational presence in Minneapolis, USA. The company recently completed a U.S. initial public offering, dual-listing, and re-domiciliation to the United States in late 2024 to support the continued development and commercialization of its product pipeline, including advancing its PARADIGM Trial.
Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors
Anteris adds Susan Knight, Stephen Denaro to board as company advances heart valve strategy
Anteris advances PARADIGM trial as Q1 cash burn reflects commercialisation push
Anteris Announces Results for the First Quarter of 2026
Anteris Announces Results for the First Quarter of 2026
Whirlpool cuts forecast, suspends dividend as Iran war hammers demand
Dow Jones set for flat start as market await Iran response to US peace deal
JD Sports preview: signs of recovery in focus ahead of World Cup
Voyager Technologies narrows loss in Q1 as revenue comes in below expectations
Nasdaq and S&P surge to new records on Iran deal hopes, AMD and Disney gains
Small Cap Watch: Small Ordinaries edges higher as company news flow continues
Anteris treats first US patients in DurAVR pivotal trial
Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial
Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial
Anteris Technologies Global Corp. (NASDAQ:AVR) Short Interest Update
Reviewing Anteris Technologies Global (NASDAQ:AVR) and Glaukos (NYSE:GKOS)
A new valve, a new playbook: How Anteris is trying to reshape a $10B heart market
Tilray Brands’ strong cannabis sales and upbeat outlook keeps Jefferies analysts bullish
GLP-1 wars: Lilly's FDA-approved oral weight-loss pill puts Novo Nordisk's Wegovy franchise under fresh pressure
Smart automation bots and the future of forex trading